Oruka Therapeutics, Inc. Form 4 Filings

Oruka Therapeutics, Inc. Chief Medical Officer Joana Goncalves exercised employee stock options for 3,500 common shares at $6.84 per share and employee warrants for 3,500 common shares at $7.80 per share on October 15, 2026. On the same date, she sold 7,000 common shares in five transactions, with reported weighted-average prices from $73.8894 to $77.7100 per share. The sales were effected pursuant to a Rule 10b5-1 trading plan entered into September 19, 2025.

Oruka Therapeutics, Inc. (ORKA) Senior Vice President, Finance Arjun Agarwal exercised options for 9,999 common shares on October 12, 2026: 8,541 shares at an exercise price of $12.50 per share and 1,458 at $34.39 per share. He also reported sales totaling 9,999 shares that day. The sales were made under a Rule 10b5-1 trading plan entered into on February 11, 2026.

Oruka Therapeutics CEO Lawrence Otto Klein exercised warrants for 25,000 common shares on October 1, 2026, at an exercise price of $7.80 per share. On the same date, he sold 25,000 shares in three transactions: 16,246 at a weighted-average price of $83.3979, 8,554 at $84.0256, and 200 at $84.7800. The sales were made under a Rule 10b5-1 trading plan entered into May 14, 2026. His reported position following the warrant transaction was 1,528,513 shares.

Oruka Therapeutics, Inc. (ORKA) reported that Senior Vice President, Finance Arjun Agarwal sold 533 shares of common stock on September 21, 2026 at $95.75 per share in an open-market or private transaction. After this sale, he held 14,219 shares directly. The transaction was effected under a Rule 10b5-1 trading plan entered into on February 11, 2026.

Oruka Therapeutics, Inc. (ORKA) reported that its General Counsel, Paul T. Quinlan, exercised employee warrants for 10,000 shares of common stock at an exercise price of $7.80 per share on September 21, 2026. The 10,000 resulting common shares were then sold in multiple open-market transactions the same day at weighted average prices in the low-to-mid $90s per share, pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. Following the exercise, Quinlan continues to hold 79,996 employee warrant shares at a $7.80 exercise price expiring on July 14, 2034.

Oruka Therapeutics, Inc. reported that Chief Medical Officer Joana Goncalves exercised employee equity awards and sold shares on September 15, 2026. She exercised options for 3,500 shares at $6.84 per share and employee warrants for 3,500 shares at $7.80 per share, acquiring 7,000 shares of common stock. She then sold an aggregate of 7,947 common shares in a series of transactions at weighted average prices generally in the low- to mid-$90s, including sales made under a Rule 10b5-1 trading plan entered into on September 19, 2025 and a separate automatic sell-to-cover transaction to satisfy tax withholding on vested restricted stock units. Following the derivative exercises, she continued to hold 193,563 option shares and 164,992 warrant shares directly.

Oruka Therapeutics, Inc. (ORKA) reported that Senior Vice President, Finance Arjun Agarwal exercised employee stock options and sold common shares. On September 11, 2026, he exercised options for 8,000 shares at $12.50 and 1,459 shares at $34.39, then sold an aggregate 9,459 shares in multiple transactions between about $91.11 and $94.02 per share pursuant to a Rule 10b5-1 trading plan adopted February 11, 2026. On September 15, 2026, he sold 560 shares at $95.71 under an automatic sell-to-cover procedure for RSU tax withholding.

Oruka Therapeutics, Inc. (ORKA) reported that Chief Executive Officer and director Lawrence Otto Klein had 2,452 shares of common stock sold on September 15, 2026 at $95.71 per share. The company states these sales were automatic, non-discretionary sell-to-cover transactions for tax withholding on vested restricted stock units, leaving Klein with 923,128 shares held directly.

Oruka Therapeutics, Inc. (ORKA) reported that General Counsel Paul T. Quinlan sold 1,039 shares of common stock on September 15, 2026 at $95.71 per share. According to the company, this automatic, non-discretionary sale was a sell-to-cover transaction to satisfy tax withholding obligations from vesting restricted stock units, leaving him with 29,995 directly held shares.

Oruka Therapeutics, Inc. (ORKA) reported that Chief Operating Officer Laura Lee Sandler sold 906 shares of common stock on September 15, 2026 at $95.71 per share. According to a footnote, this was an automatic, non-discretionary sell-to-cover transaction to satisfy tax withholding from vesting restricted stock units, leaving her with 235,478 shares held directly.

Oruka Therapeutics, Inc. (ORKA) reported insider transactions by Chief Operating Officer Laura Lee Sandler on September 1, 2026. Sandler exercised 5,000 Employee Warrants at an exercise price of $7.80 per share into common stock, then sold 5,000 common shares in two open‑market transactions at weighted average prices around $91–$92 per share. Following the warrant exercise, Sandler held 74,996 Employee Warrants directly. The sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

Oruka Therapeutics, Inc. (ORKA) reported that Chief Executive Officer and director Lawrence Otto Klein exercised an employee warrant to acquire 75,000 shares of common stock at an exercise price of $7.80 per share and on the same date sold 75,000 shares of common stock in multiple open-market transactions. The sales, totaling 6,604, 63,596 and 4,800 shares, were executed at weighted average prices of $90.79, $91.90 and $92.44 per share, respectively, under a Rule 10b5-1 trading plan entered into on May 14, 2026. Following the exercise, Klein continued to hold 1,553,513 employee warrant shares, which expire on July 14, 2034.

Oruka Therapeutics, Inc. (ORKA) reported that Chief Commercial Officer Larry Todd Edwards received equity awards on August 24, 2026. He was granted 100,000 shares of Common Stock and an option to purchase 20,000 shares of Common Stock at an exercise price of $102.42 per share, both held directly.

The 100,000-share stock grant vests as to one-quarter on September 14, 2027, with the remaining three-quarters vesting in 12 equal quarterly installments thereafter. The 20,000-share option vests as to one-quarter of the underlying shares on August 24, 2027 and then 1/48 of the underlying shares monthly thereafter, and expires on August 23, 2036. The filing does not indicate use of a Rule 10b5-1 trading plan.

Oruka Therapeutics, Inc. executive Joana Goncalves (Chief Medical Officer) reported a series of equity transactions on August 17, 2026. She exercised 3,500 stock options at $6.84 and 3,500 employee warrants at $7.80 to acquire a total of 7,000 shares of common stock, then sold 7,000 shares in multiple open-market transactions at weighted average prices between approximately $109.05 and $112.86. Following these exercises, she held 197,063 options and 168,492 warrants directly. The sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

Oruka Therapeutics’ General Counsel, Paul T. Quinlan, reported option activity and sales on August 14, 2026. He exercised derivative awards covering 52,000 shares of common stock at exercise prices of $7.80 and $12.50 per share, then sold 52,000 shares of common stock in multiple transactions at weighted-average prices between roughly $105.53 and $111.22. The company confirms these sales were effected under a Rule 10b5-1 trading plan entered into on May 15, 2026. Following the exercises, he reports remaining derivative positions of 89,996 Employee Warrants and 120,500 Employee Stock Options.

Oruka Therapeutics, Inc. Senior Vice President, Finance Arjun Agarwal reported option exercises and share sales in Oruka Therapeutics, Inc. stock. On 2026-08-13 he exercised options for 10,000 shares of common stock (8,542 at $12.50 and 1,458 at $34.39 per share) and on the same date sold 10,000 shares in multiple transactions at weighted average prices between $104.6734 and $108.4628 per share. The sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

Oruka Therapeutics, Inc. Chief Medical Officer Joana Goncalves reported same-day option exercises and stock sales on July 15, 2026. She exercised awards for 7,000 common shares at strike prices of $6.84 and $7.80, then sold 7,000 shares in open-market transactions under a pre-arranged Rule 10b5-1 trading plan, with weighted-average sale prices in ranges spanning $83.87 to $87.26 per share.

Oruka Therapeutics, Inc. Senior Vice President, Finance Agarwal Arjun reported open-market sales of common stock and exercises of employee stock options on July 13, 2026. He sold a total of 9,999 shares of common stock in multiple open-market transactions at weighted-average prices between $82.49 and $85.69 per share, pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. On the same date, he exercised employee stock options to acquire 9,999 shares of common stock at exercise prices of $34.39 and $12.50 per share.

Fairmount Healthcare Fund II L.P., an entity managed by Fairmount Funds Management LLC, converted 42,641 shares of Series B Preferred Stock of Oruka Therapeutics, Inc. into 3,553,410 shares of Common Stock on July 1, 2026 for no cash consideration, in line with the Series B terms.

On the same date, Fairmount Healthcare Fund II L.P. sold 3,553,410 Common shares at $84.43 per share, and reported 1,131,954 Common shares held indirectly afterward, along with 94,497 Series B Preferred shares remaining outstanding. A related vehicle, Fairmount Healthcare Co-Invest III L.P., reported indirect holdings of 2,573,308 Common shares. Fairmount Funds Management LLC and its managers Peter Harwin and Tomas Kiselak disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.

Oruka Therapeutics, Inc. Chief Operating Officer Laura Lee Sandler reported a set of routine equity transactions. She sold a total of 5,000 shares of common stock in open-market trades at weighted average prices in the mid‑$90s per share, executed under a Rule 10b5‑1 trading plan entered into on September 19, 2025.

On the same date, she exercised an employee warrant to acquire 5,000 shares of common stock at an exercise price of $7.80 per share, fully converting this derivative position. Following these transactions, she directly holds 236,384 shares of Oruka Therapeutics common stock.

Oruka Therapeutics, Inc. Senior Vice President of Finance Arjun Agarwal reported selling 1,587 shares of Common Stock in open-market transactions. The sales occurred at prices of about $82.15 and $80.01 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan entered into on February 11, 2026.

Oruka Therapeutics, Inc. Senior Vice President, Finance Arjun Agarwal reported a mix of option exercises and related share sales in company common stock. On June 12, 2026, he exercised employee stock options for 8,000 shares at $12.50 per share and 1,459 shares at $34.39 per share, increasing his direct holdings.

On the same day and on June 15, 2026, he sold an aggregate of 9,854 shares of common stock in multiple open-market transactions at weighted average prices ranging from about the high $60s to around $70 per share. According to the footnotes, these sales were carried out under Oruka’s automatic, non-discretionary sell-to-cover procedure to satisfy tax withholding obligations tied to vesting of restricted stock units and were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

Following these transactions, Agarwal directly holds 16,899 shares of Oruka Therapeutics common stock. The filing also notes that his holdings include 888 shares acquired through the company’s stock purchase plan on June 8, 2026.

Oruka Therapeutics Chief Medical Officer Joana Goncalves reported option-related trades and share sales in Oruka Therapeutics, Inc. common stock. On June 15, 2026, she exercised options and warrants to acquire 7,000 shares at exercise prices of $7.80 and $6.84 per share, and sold 7,947 shares in multiple open-market transactions at weighted-average prices around $68–$71 per share.

Following these transactions, she directly held 32,718 shares of common stock. According to the footnotes, some sales were made under a pre-arranged Rule 10b5-1 trading plan entered into on September 19, 2025, and other sales were automatic sell-to-cover transactions to satisfy tax withholding obligations from vesting restricted stock units, indicating a largely routine, pre-planned liquidity and tax-management pattern.

Oruka Therapeutics, Inc.'s Chief Executive Officer Lawrence Otto Klein reported an automatic sale of 1,729 shares of common stock at $69.69 per share. According to the footnote, this was carried out under the company’s automatic, non-discretionary sell-to-cover procedure to satisfy tax withholding obligations from vesting restricted stock units.

After this tax-related sale, Klein directly holds 925,580 shares of Oruka Therapeutics common stock. Because the transaction was solely to cover taxes and was not discretionary, it functions more like a routine payroll event than an active decision to reduce his investment.

Oruka Therapeutics, Inc. Chief Operating Officer Laura Lee Sandler reported an open-market sale of 600 shares of common stock at $69.69 per share. The sale was executed under the company’s automatic, non-discretionary sell-to-cover procedure to satisfy tax withholding obligations from vested restricted stock units.

After this transaction, Sandler directly holds 236,384 shares of Oruka Therapeutics common stock. The filing reflects a small, tax-driven disposition rather than a discretionary change in her overall ownership stake.

Oruka Therapeutics, Inc. General Counsel Paul T. Quinlan reported an automatic sale of 733 shares of common stock at $69.69 per share. The sale was executed under the company’s non-discretionary sell-to-cover procedure to satisfy tax withholding from restricted stock unit vesting. After this transaction, he holds 31,034 shares directly, so the sale represents a small portion of his ownership and reflects a tax-related mechanism rather than a discretionary trade.

Oruka Therapeutics director Carl Dambkowski reported planned share sales. He sold 22,417 shares of common stock on June 11, 2026 at a weighted average price of $70.1343 per share, followed by 12,583 shares on June 12, 2026 at $70.1090 per share in open-market transactions. According to a footnote, these sales were made under a pre-arranged Rule 10b5-1 trading plan. After the transactions, he directly holds 38,743 Oruka Therapeutics shares.

Oruka Therapeutics director Carl Dambkowski received a grant of 9,136 stock options on Common Stock. These options have an exercise price of $55.23 per share and expire on June 1, 2036. The grant was a compensation-related award, bringing his directly held stock options to 9,136. According to the vesting terms, the option vests as to 1/12 of the underlying shares monthly beginning on June 2, 2026, so the award becomes exercisable gradually over time rather than immediately.

Oruka Therapeutics, Inc. director Samarth Kulkarni received a grant of options covering 9,136 shares of common stock. The options have an exercise price of $55.23 per share and expire on June 1, 2036. According to the footnote, the award vests in equal monthly installments over 12 months starting June 2, 2026.

Oruka Therapeutics director Martin Christopher Nathan received a grant of stock options for 9,136 shares of common stock. These options have an exercise price of $55.23 per share and expire on June 1, 2036. The award vests in equal monthly installments over 12 months starting June 2, 2026, aligning the director’s compensation with future company performance.

BALL KRISTINE M reported acquisition or exercise transactions in this Form 4 filing.

Oruka Therapeutics director Kristine M. Ball received a grant of stock options covering 9,136 shares of common stock at 55.23 per share. The options vest in 12 equal monthly installments beginning on June 2, 2026 and expire on June 1, 2036. Following this award, she holds options for 9,136 shares directly.

Oruka Therapeutics, Inc. reported that investment vehicles managed by Fairmount Funds Management received a new stock option grant linked to its common stock. The option covers 9,136 shares with an exercise price of $55.23 per share and expires on June 1, 2036.

The option vests in equal monthly installments of 1/12 starting on June 2, 2026, contingent on continued service to Oruka Therapeutics. The filing explains that Peter Harwin holds the option for one or more Fairmount-managed funds and must deliver any net cash or stock from the option to Fairmount for those funds’ benefit.

Fairmount, Harwin, and Tomas Kiselak each disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest. The transaction is characterized as a grant or award acquisition of a derivative security, rather than an open-market trade.

Oruka Therapeutics director Carl Dambkowski reported a mix of stock sales and option exercises in Oruka Therapeutics, Inc. common stock. On May 21, 2026, he sold a total of 105,000 shares in open‑market transactions at weighted average prices around $58–$60 per share under a pre‑arranged Rule 10b5‑1 trading plan. On the same date, he exercised stock options and warrants covering 62,260 shares at exercise prices of $6.84, $7.80, and $11.77 per share, converting derivative awards into common stock. He continues to hold unexercised options and warrants that expire between 2034 and 2035.

Oruka Therapeutics, Inc. Senior Vice President, Finance Arjun Agarwal reported a mix of stock option exercises and share sales in Oruka common stock. On May 18, 2026, he exercised 7,833 employee stock options at exercise prices of $34.39 and $12.50 per share, converting derivative awards into common shares. The same day, he sold 10,290 common shares in open-market transactions under a pre-arranged Rule 10b5-1 trading plan, at weighted average prices spanning approximately $57.72 to $61.76 per share. This pattern reflects routine option exercise paired with partial share sales for liquidity under a pre-planned program.

Oruka Therapeutics, Inc.’s Chief Medical Officer, Joana Goncalves, reported option exercises and related share sales. On May 15, 2026, she exercised options and warrants to acquire a total of 7,000 shares of common stock at exercise prices of $7.80 and $6.84 per share. On the same date, she sold an aggregate 7,000 common shares in open-market transactions at weighted-average prices of about $61.56, $62.42 and $63.52 per share pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. Following these transactions, she directly owned 33,377 shares of Oruka Therapeutics common stock.

Oruka Therapeutics, Inc. Chief Operating Officer Laura Lee Sandler reported multiple transactions in the company’s common stock. On May 1, 2026, she completed open-market sales totaling 5,000 shares at weighted average prices within ranges from $62.33 to $67.20 per share under a pre-established Rule 10b5-1 trading plan.

On the same date, she also exercised employee warrants to acquire 5,000 shares of common stock at an exercise price of $7.80 per share. The warrant covers 5,000 underlying shares, vests over time beginning April 3, 2025, and is scheduled to expire on July 14, 2034.

Oruka Therapeutics Chief Medical Officer Joana Goncalves exercised employee derivatives and sold shares in a routine, pre-planned transaction. She exercised 3,500 employee stock options at $6.84 per share and 3,500 employee warrants at $7.80 per share, receiving 7,000 shares of common stock.

On the same date, she sold 7,000 common shares in open-market transactions at weighted average prices of $65.73, $66.56 and $67.38, pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. Following these trades, she directly holds 33,377 shares of Oruka Therapeutics common stock, along with substantial remaining options and warrants.

Oruka Therapeutics, Inc. Chief Executive Officer Lawrence Otto Klein reported an open-market sale of 1,729 shares of common stock at $41.30 per share. According to the filing, this sale was executed automatically under the company’s non-discretionary sell-to-cover procedure to satisfy tax withholding tied to vested restricted stock units. After this transaction, Klein directly holds 927,309 shares of Oruka Therapeutics common stock, indicating he retains a substantial equity position following the tax-related sale.

Oruka Therapeutics, Inc. senior vice president of finance Arjun Agarwal reported an automatic sale of common stock tied to tax withholding on vested restricted stock units. A total of 395 shares were sold on March 16, 2026 at $41.30 per share under the company’s non-discretionary sell-to-cover procedure. After this tax-related transaction, Agarwal directly holds 18,863 shares of Oruka common stock.

Oruka Therapeutics, Inc. Chief Operating Officer Laura Lee Sandler reported an automatic sale of 600 shares of common stock at $41.30 per share. The footnote explains that these sales were made under the company’s automatic, non-discretionary sell-to-cover procedure to satisfy tax withholding obligations from vesting restricted stock units. After this tax-related sale, Sandler directly holds 236,984 shares of Oruka common stock.

Oruka Therapeutics Chief Medical Officer Joana Goncalves exercised equity awards and sold shares in a pre-planned, tax-related transaction. She exercised employee stock options and an employee warrant covering a total of 7,000 shares of common stock at exercise prices of $6.84 and $7.80 per share.

On the same date, she sold 7,641 shares of common stock in multiple open-market transactions at weighted average prices between approximately $39.65 and $42.28. The filing states these sales were made under a Rule 10b5-1 trading plan and Oruka’s automatic, non-discretionary sell-to-cover procedure for tax withholding. Following the transactions, she directly holds 33,377 common shares.

Oruka Therapeutics General Counsel Paul T. Quinlan reported a small, tax-related share sale. On the vesting of restricted stock units, 733 shares of common stock were automatically sold at $41.30 per share under the company’s non-discretionary sell-to-cover procedure to satisfy tax withholding. After this transaction, he directly holds 31,767 shares.

Oruka Therapeutics, Inc. Chief Operating Officer Laura Lee Sandler reported a combination of option exercise and share sales. She exercised an employee warrant for 5,000 shares of common stock at $7.80 per share and received common stock.

On the same date, she sold 5,000 shares of common stock in open-market transactions, including 2,325 shares at a weighted average price of $33.2843 and 2,675 shares at a weighted average price of $33.8077. The sales were made under a pre-arranged Rule 10b5-1 trading plan. After these transactions, she directly owned 237,584 shares of Oruka Therapeutics common stock.

Oruka Therapeutics Chief Medical Officer Joana Goncalves reported option exercises and stock sales in Common Stock of Oruka Therapeutics, Inc. On February 17, 2026, she exercised an Employee Stock Option for 3,500 shares at $6.84 and an Employee Warrant for 3,500 shares at $7.80, acquiring Common Stock through derivative conversion.

On the same date, she conducted open-market sales of 6,064 shares at a weighted average price of $32.3009 and 936 shares at a weighted average price of $32.7842, under a Rule 10b5-1 trading plan entered into on September 19, 2025. After these transactions, she directly owned 34,018 shares of Common Stock, plus 218,063 employee stock options and 189,492 employee warrants outstanding.

Oruka Therapeutics Chief Medical Officer Joana Goncalves received new equity awards in the form of stock and options. On January 23, 2026, she was granted 32,500 shares of common stock at a price of $0 per share, bringing her directly held common stock to 34,018 shares. This stock grant vests in equal sixteenth portions on each March 14, June 14, September 14, and December 14.

On the same date she was also granted an employee stock option for 130,000 shares of Oruka Therapeutics common stock at an exercise price of $34.39 per share. The option vests in 1/48 monthly installments starting from January 1, 2026 and is scheduled to expire on January 22, 2036. Both the stock and option positions are reported as held directly.

Oruka Therapeutics, Inc. disclosed that Chief Operating Officer Laura Sandler received new equity awards on January 23, 2026. She was granted 32,500 shares of common stock at a price of $0 per share, increasing her directly held common stock to 237,584 shares. The stock grant vests in 1/16 increments on each March 14, June 14, September 14 and December 14.

She also received an employee stock option covering 130,000 shares of common stock at an exercise price of $34.39 per share, expiring on January 22, 2036. This option vests as to 1/48 of the underlying shares monthly starting from January 1, 2026, and is held directly.

Oruka Therapeutics senior vice president of finance Arjun Agarwal reported new equity awards. On January 23, 2026, he received an employee stock option for 70,000 shares of common stock at an exercise price of $34.39 per share, with the option vesting in 1/48 monthly installments from January 1, 2026. He also acquired 17,500 shares of common stock at a stated price of $0, vesting in 1/16 installments on each March 14, June 14, September 14 and December 14. Following these transactions, he directly beneficially owned 19,258 common shares, including 1,758 shares previously acquired under the Oruka stock purchase plan.

Oruka Therapeutics, Inc. reported that Chief Executive Officer and director Lawrence Otto Klein received new equity awards on January 23, 2026. He was granted 306,700 employee stock options with an exercise price of $34.39 per share, covering the right to buy 306,700 shares of common stock, for which he paid $0 at grant. These options vest as to 1/48 of the underlying shares monthly starting January 1, 2026 and expire on January 22, 2036. In addition, he acquired 76,700 shares of common stock at a price of $0, bringing his directly held common stock position to 929,038 shares. That stock grant vests in 1/16 increments on each March 14, June 14, September 14, and December 14, or the prior trading day if needed.

Oruka Therapeutics, Inc. reported that its General Counsel, Paul T. Quinlan, received new equity awards on January 23, 2026.

He acquired 32,500 shares of common stock at a price of $0, held directly. This grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day).

Quinlan was also granted an employee stock option for 130,000 shares of common stock at an exercise price of $34.39 per share, expiring on January 22, 2036. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.